Cantor Fitzgerald Maintains a Buy Rating on Genesis Healthcare (GEN)


In a report released today, Joseph France from Cantor Fitzgerald maintained a Buy rating on Genesis Healthcare (NYSE: GEN), with a price target of $7. The company’s shares closed yesterday at $1.28.

France noted:

“We rate GEN $7 price target. We believe that the company is well- positioned to capitalize on the growing post-acute-care market and that its stronger and still-improving capital structure and the further development of value-based reimbursement initiatives will drive faster earnings growth. We expect profitability to improve as the company becomes a more-important player in the post-acute-care market by lowering unanticipated hospital readmissions. $7 price target is based on a blend of DCF and comparable-company analysis.”

According to TipRanks.com, France is a 5-star analyst with an average return of 10.0% and a 58.2% success rate. France covers the Services sector, focusing on stocks such as Cross Country Healthcare, Five Star Quality Care, and Addus Homecare Corp.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Genesis Healthcare with a $7 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.86 and a one-year low of $0.60. Currently, Genesis Healthcare has an average volume of 595.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genesis Healthcare, Inc. is a holding company, which engages in the provision of inpatient services through skilled nursing and assisted and senior living communites. It also offers rehabilitation and respiratory therapy services. It operates through the following segments: Inpatient, Rehabilitation Therapy, and Other Services.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts